Agenus Inc.

NASDAQ:AGEN

Biotechnology

Healthcare
$6.40 -0.17%

-$0.01 today

Market cap
$289.58M
Beta
1.54
P/E (TTM)
1.7
EPS (TTM)
$1.70
52W Low $2.71High $7.34

Volume 0.88M

Average 0.82M

AGEN Common Stock Issued

Cash raised by issuing new shares.

Agenus Inc.NASDAQ: AGEN

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued grows, but more slowly than its trailing trend

Q1 FY2026 common stock issued of $7.47M rose 17.8% year over year, behind the +33.3% change in trailing-twelve-month common stock issued. Sequentially, it fell 13.7% from the prior quarter. Over 3 fiscal years it compounded at -28.5% a year.

Context

  • Common stock issued amounted to 31.8% of revenue in FY2025, down 5.7 pp from a year earlier.
  • Common stock issued increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +17.8% toward the trailing-twelve-month pace of +33.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.47M-13.7% QoQ
Last fiscal yearDec 2025
$36.31M-6.5% YoY
LTMMar 2026
$37.31M+33.3% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.8%——
1 year-6.5%——
3-year CAGR-28.5%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
36.31M USD
Year-over-year change
-6.5%
4-year CAGR
-36.3%

Common Stock Issued vs competitors

How AGEN compares with its peers on the latest reported figures

  • AGEN's LTM Mar 2026 common stock issued of $37.31M is the 3rd largest of the 10 companies compared; the peer median is $449K.
  • Its year-over-year change of +33.3% is the 4th highest of 7, against a peer median of +55.4%.
  • Common stock issued amounts to 30.1% of revenue for AGEN, versus a peer median of 3.0%.
AGEN Competitors Peer median
Common Stock Issued for AGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRDOpus Genetics, Inc.LTM Mar 2026$56.66M +577.7%+123.1%472.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$53.14M +10.8%-13.8%—
AGENAgenus Inc.LTM Mar 2026$37.31M +33.3%-28.5%30.1%
HURATuHURA Biosciences, Inc.LTM Mar 2026$22.86M —+125.9%—
TTRXTurn Therapeutics Inc.LTM Mar 2026$5.92M ———
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$4.14M -1527.6%——
SEERSeer, Inc.LTM Mar 2026$449K ——3.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$147K +210.5%-78.3%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$146K -96.1%-86.2%—
FATEFate Therapeutics, Inc.LTM Mar 2026$0 +100.0%—0.0%
Peer median (excluding AGEN) $449K+55.4%-13.8%3.0%

Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.72M)(230.66M)(257.44M)(232.27M)(232.27M)
Depreciation & Amortization6.79M6.95M13.59M13.34M13.34M
Deferred Income Tax00000
Stock-Based Compensation19.58M18.34M22.87M17.39M17.39M
Change in Working Capital(9.74M)24.08M10.76M32.6M27.33M
Accounts Receivables(394K)122K(23.46M)25.34M(1.73M)
Inventory00000
Accounts Payables10.82M6.49M21.37M2.01M23.5M
Other Working Capital(20.17M)17.47M12.85M5.25M5.56M
Other Non-Cash Items22.25M5.92M(13.98M)10.62M15.89M
Operating Cash Flow10.15M(175.37M)(224.2M)(158.32M)(158.32M)
Capital Expenditures(33.81M)(53.06M)(9.95M)(576K)(576K)
Acquisitions (Net)0(2.92M)000
Purchases of Investments(14.99M)(24.63M)(20.04M)00
Sales of Investments025M30.03M579K579K
Other Investing Activities5.66M22M3.36M24K24K
Investing Cash Flow(43.15M)(33.61M)3.4M27K27K
Debt Repayment(1.32M)(490K)(8.93M)9.52M2.35M
Common Stock Issued220.65M99.21M133.16M38.82M36.31M
Common Stock Repurchased(1.65M)(3.79M)(5.17M)0(87K)
Dividends Paid00000
Other Financing Activities7.59M898K807K74.5M84.27M
Financing Cash Flow225.26M95.83M119.87M122.84M122.84M
Effect of Forex Changes(164K)(104K)(628K)(260K)(260K)
Net Change in Cash192.1M(113.26M)(101.56M)(35.71M)(35.71M)
Free Cash Flow(23.67M)(228.44M)(234.16M)(158.89M)(158.89M)

Agenus Inc.

NASDAQ:AGEN

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.